Related Experiment Videos
Percutaneous transvenous mitral commissurotomy for restenosis after surgical mitral valvotomy
V K Bahl1, S Chandra, K K Talwar
1Cardiothoracic Centre, All India Institute of Medical Sciences, New Delhi.
Insights
Percutaneous transvenous mitral commissurotomy (PTMC) effectively treats restenosis after surgical valvotomy. This minimally invasive procedure safely improves mitral valve function and patient outcomes in patients with prior surgical history.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiac Surgery
Background:
- Mitral restenosis is a significant complication following surgical valvotomy.
- Patients with restenosis often present with severe symptoms and functional limitations.
Purpose of the Study:
- To evaluate the safety and efficacy of percutaneous transvenous mitral commissurotomy (PTMC) in patients with restenosis after prior surgical valvotomy.
- To assess the impact of PTMC on mitral valve area, hemodynamic parameters, and functional status.
Main Methods:
- PTMC was performed in 350 patients, with 51 identified as having restenosis post-surgical valvotomy.
- Hemodynamic parameters including mitral valve area and transmitral gradients were measured before and after PTMC.
- Clinical follow-up, including New York Heart Association (NYHA) functional class, was assessed post-procedure.
Main Results:
- PTMC significantly increased mitral valve area (0.82 to 1.9 cm2) and cardiac index (1.9 to 2.8 l/min/m2).
- Mean transmitral gradients decreased significantly (29 to 6 mmHg) post-PTMC.
- At 24 weeks, 96% of patients improved to NYHA class I or II, with outcomes comparable to patients without prior surgery.
Conclusions:
- PTMC is a safe and effective treatment for mitral restenosis in patients with a history of surgical valvotomy.
- The procedure leads to significant hemodynamic improvements and functional class amelioration.
- Subvalvular fibrosis and duration from prior surgery did not negatively impact outcomes on univariate analysis.
Abstract:
Percutaneous transvenous mitral commissurotomy (PTMC) was performed in 350 patients. Of these patients, 51 (15%) (30 women and 21 men, aged 32 +/- 11 years) had restenosis 11 +/- 4 years following surgical valvotomy. Forty (79%) patients were in New York Heart Association (NYHA) class III and 11 (21%) were in class IV. PTMC resulted in an increase in mitral valve area from 0.82 +/- 0.3 to 1.9 +/- 0.2 cm2 (p < 0.001), an increase in cardiac index from 1.9 +/- 0.4 to 2.8 +/- 0.5 l/min/m2 (p < 0.001), and a decrease in mean transmitral gradients from 29 +/- 4 to 6 +/- 4 mmHg (p < 0.001). The results did not differ from those observed in 299 patients without prior surgical valvotomy. On univariate analysis, the subvalvular fibrosis, assessed angiographically, and the duration from prior surgery were not found to influence the overall outcome. At 24 weeks, 46 of 48 (96%) patients in whom clinical follow-up was available, were found to be in NYHA class I and 2 (4%) patients were in class II. Thus, PTMC is a safe and effective procedure for patients with mitral restenosis following surgical valvotomy.